ANGEL-MS
A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis
What was tested
Treatment tested
- Temelimab
Syncytin-1 inhibitor
What it measured
Main measures
The following parameters will be evaluated to assess the long term safety of GNbAC1:
Safety
Other measures (1)
The following parameters will be evaluated to assess the long term efficacy of GNbAC1:
Papers
Loading reviews and guidelines…
Related trials
- The TAF-MS study
Phase 2 · Completed
Results posted, no main test reported
- Multimodal Exploration of Patients With Multiple Sclerosi…
Not a drug-phase study · Status unknown
No result found
- ProTEct-MS Extension
Phase 2 · Stopped early
Stopped early
- ProTEct-MS
Phase 2 · Completed
Results posted, no main test reported
- LemKids
Phase 3 · Stopped early
Stopped early
- ANGEL-MS
Phase 2 · Stopped early
Stopped early
History
- In scope changed from true to false
Started
Feb 2017
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error